Search results
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview the most anticipated late-breaking and featured science trials of ACC.23.
Which trials have the potential to change practice? What are the key considerations for patient care and research? What is the context of the top trials of ACC?
Trials covered in detail include:
…
View more
Author(s):
D Scott Lim
Added:
10 months ago
EuroPCR 23 - Dr Scott Lim (UVA Health Heart and Vascular Center, US) joins us to discuss the findings of the DRAGONFLY-DMR trial. (NCT04734756)
The purpose of the study was to assess the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system (Hangzhou Valgen Medtech) for treating symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation (DMR…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen interprets the findings from the top 10 ACC.23/WCC late-breaking and featured science trials and studies in their critical View from the Thoraxcenter review series. Join them as they consider the implications for research and offer an insight into how they will incorporate the latest data into their day-to-day clinical practice.
What are the top…
View more
Author(s):
Michele De Bonis
,
Ottavio Alfieri
Added:
3 years ago
Degenerative mitral regurgitation (MR) represents a rather common pathology, affecting 1–2% of the general population. In patients requiring surgery for this disease, mitral valve repair is the standard of care. Whenever feasible it is preferable to prosthetic replacement, as it provides better preservation of left ventricular (LV) function, higher survival, lower rates of thromboembolism and…
View more
Author(s):
Eduardo Alegria-Barrero
,
Olaf W Franzen
Added:
3 years ago
Diseases of the mitral valve (MV) are the second most frequent clinically significant form of valvular disease in adults. In particular, MV regurgitation occurs with increasing frequency as part of degenerative changes in the ageing process.1
The annual incidence of degenerative MV disease is estimated at approximately 2–3 %. In addition to degenerative valve disease, MV regurgitation can be…
View more
Alex Pui-Wai Lee
Author
TCT 2018: TRIVALVE
Author(s):
Jorg Hausleiter
Added:
5 years ago
Video
TCT 2022 Late-Breaking Science Collection
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Video Series
Author(s):
Ottavio Alfieri
,
Michele De Bonis
Added:
3 years ago
Despite the absence of randomised comparison, it is widely accepted that, when feasible, valve repair is the optimal surgical treatment in patients with severe degenerative mitral regurgitation (MR) due to the well documented advantages of such an approach over valve replacement in terms of perioperative mortality, preservation of postoperative left ventricular (LV) function and long-term…
View more
Author(s):
Khung Keong Yeo
,
Jack Wei Chieh Tan
,
David WM Muller
,
et al
Added:
2 years ago